GSK Encourages Open Innovation and R&D GlaxoSmithKline (GSK) has outlined the measures it is taking as part of a new open innovation approach to R&D, including opening up its tuberculosis compound library, investing in its open laboratory in Spain, and sharing detailed clinical trial data with researchers. More...
Teva Opens New Sterile Plant in Hungary Teva has invested $110 million in a new sterile plant in Gödöllo, Hungary with an annual production capacity of 160–200 million units of injection products in six production lines. More...
New USP Standards Guide Prescription Container Labels The US Pharmacopeial Convention (USP) released standards that, for the first time, provide a universal approach to organizing labels for prescription containers dispensed by pharmacists. More...
Get the Latest Updates on Twitter We regularly tweet the latest news and rumours hitting the web about the pharmaceutical industry. Follow us to keep up to date. More...
Realize Effective Pharmaceuticals
Reliable solutions enable pharmaceutical scientists to innovate in disease research, accelerate drug discovery and have greater confidence throughout development and manufacturing. Agilent solutions in genomics research, automation, separation and detection technologies along with workflow driven software solutions helps deliver the answers to bring effective therapeutics to market.
Learn more at www.agilent.com/lifesciences/realizepharma
Agilent
Agilent ICP-MS/ICP-OES
Reliable solutions for regulated pharmaceutical laboratories Complying with new elemental impurity limits as defined by draft USP methods <232>/<233> could pose a significant challenge. You need to choose qualified hardware and software, ensure verification, and maintain electronic records. But there is a simple answer – Request a free copy of our primer on Elemental Impurity Analysis to learn more.
Event Profile
Special Supplement
PHARM Connect Congress 2013
February 27- 28 2013 Budapest, Hungary The Annual PHARM Connect Congress for Enlarged Europe is one of the largest pharmaceutical and biotechnology manufacturing events in Central and Eastern Europe and the CIS market in 2013. Read more
Special Supplement
Solubilization Solutions
In a special PharmTech issue, current and emerging bioavailability challenges are examined. Articles address solutions and approaches for solubilization as related to solid dispersions by hot-melt extrusion, lipophilic excipients, lipid-based formulations, spray drying, and more. Read more
Do you think the growing number of anticounterfeiting technologies, coupled with increased focus from regulators, have had a positive impact on reducing the number of counterfeit pharmaceuticals in the legal supply chain?
Yes
53%
No
14%
Technologies have; regulations are still inadequate
26%
Regulations have; technologies are still inadequate
7%
This week we would like to know...
Concerns have recently been raised about the safety of confidential data at FDA. Do you think regulators are doing enough to protect confidential data?
